In Brief: Cortecs/Osteometer BioTech agreement
This article was originally published in The Gray Sheet
Cortecs/Osteometer BioTech agreement: U.K.-based oral drug delivery firm Cortecs inks a development deal with Danish diagnostics firm Osteometer BioTech A/S to develop a whole blood, point-of-care diagnostic product for the detection of collagen breakdown, an indicator of osteoporosis. Cortecs, calling the deal a "profit-sharing agreement," says that the development effort will combine its rapid diagnostic technologies with Osteometer's Cross-laps bone resorption marker technology. The companies will jointly develop the product, with clinical testing coordinated by The Center for Clinical and Basic Research in Denmark. Cortecs will manufacture the finished product, retain distribution rights for the U.K. and Australia and select distributors for other markets "from international corporations involved in the management of osteoporosis"...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.